1-9 of 9
Julie Lisano
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma

Clinical Trials & Observations
Armando Santoro, Alison J. Moskowitz, Silvia Ferrari, Carmelo Carlo-Stella, Julie Lisano, Stephen Francis, Rachael Wen, Alev Akyol, Kerry J. Savage
Journal: Blood
Blood (2023) 141 (22): 2780–2783.
https://doi.org/10.1182/blood.2022017951
Published: 2023
Includes: Supplemental data
Journal Articles

Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults

Clinical Trials & Observations
Paul Harker-Murray, Christine Mauz-Körholz, Thierry Leblanc, Maurizio Mascarin, Gérard Michel, Stacy Cooper, Auke Beishuizen, Kasey J. Leger, Loredana Amoroso, Salvatore Buffardi, Charlotte Rigaud, Bradford S. Hoppe, Julie Lisano, Stephen Francis, Mariana Sacchi, Peter D. Cole, Richard A. Drachtman, Kara M. Kelly, Stephen Daw
Journal: Blood
Blood (2023) 141 (17): 2075–2084.
https://doi.org/10.1182/blood.2022017118
Published: 2023
Includes: Supplemental data
Journal Articles

Real-World Characteristics of Patients with Classical Hodgkin Lymphoma Receiving Frontline Brentuximab Vedotin with Chemotherapy: A Retrospective Analysis with Propensity Score Matching

Tycel J. Phillips, MD, Kristina Yu-Isenberg, PhD MPH, RPh, Nicholas Liu, PharmD, Andy Surinach, MPH, Carlos Flores, MPH, Julie Lisano, PharmD, Michelle A. Fanale, MD, John M. Burke, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 3–4.
https://doi.org/10.1182/blood-2020-140534
Published: 2020
Journal Articles

Real-World Characteristics of Patients with Peripheral T-Cell Lymphoma Receiving Frontline Brentuximab Vedotin with Chemotherapy: A Retrospective Analysis with Propensity Score Matching

John M. Burke, MD, Nicholas Liu, PharmD, Kristina Yu-Isenberg, PhD MPH, RPh, Michelle A. Fanale, MD, Andy Surinach, MPH, Carlos Flores, MPH, Julie Lisano, PharmD, Tycel J. Phillips, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–19.
https://doi.org/10.1182/blood-2020-140832
Published: 2020
Journal Articles

Real-World Treatment Patterns and Overall Survival Among Medicare Fee-for-Service Beneficiaries Newly Diagnosed with Peripheral T-Cell Lymphoma

Anne Shah, MS, Allison Petrilla, MPH, Mayvis Rebeira, PhD, Joseph Feliciano, PharmD, Thomas W. LeBlanc, MDMA,MHS, Julie Lisano, PharmD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3492.
https://doi.org/10.1182/blood-2019-130973
Published: 2019
Journal Articles

A Phase 2 Study of Retreatment with Brentuximab Vedotin in Patients with cHL, sALCL or Other CD30-Expressing PTCL

Sairah Ahmed, MD, Julie Lisano, PharmD, Trevor Newhook, MS
Journal: Blood
Blood (2019) 134 (Supplement_1): 4054.
https://doi.org/10.1182/blood-2019-121523
Published: 2019
Journal Articles

Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse

Clinical Trials & Observations Brief Report
Craig H. Moskowitz, Jan Walewski, Auayporn Nademanee, Tamas Masszi, Edward Agura, Jerzy Holowiecki, Muneer H. Abidi, Andy I. Chen, Patrick Stiff, Simonetta Viviani, Veronika Bachanova, Anna Sureda, Teresa McClendon, Connie Lee, Julie Lisano, John Sweetenham
Journal: Blood
Blood (2018) 132 (25): 2639–2642.
https://doi.org/10.1182/blood-2018-07-861641
Published: 2018
Journal Articles

Real World Prevalence of Diagnostic Revision Among Patients with Peripheral T-Cell Lymphomas (PTCL) in the US: Results of an Administrative Claims and Electronic Medical Record Analyses

Joseph Feliciano, PharmD, Machaon Bonafede, Donna McMorrow, Julie Park, Julie Lisano, Thomas Manley, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1633.
https://doi.org/10.1182/blood-2018-99-117104
Published: 2018
Journal Articles

Superior Clinical Benefit of Brentuximab Vedotin in Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Status in the Phase 3 ALCANZA Study

Youn H. Kim, MD, H. Miles Prince, MD FRACP, FRCPA, Sean Whittaker, MB, ChB, FRCP, MD, Steven M. Horwitz, MD, Madeleine Duvic, MD, Oliver Bechter, Jose A. Sanches, Rudolf Stadler, MD, Julia Scarisbrick, MD FRCP, MBBS, Pietro Quaglino, MD, Pier Luigi Zinzani, MD, Pascal Wolter, MD, Herbert Eradat, MD, Lauren C. Pinter-Brown, MD, Pablo L. Ortiz-Romero, Oleg E. Akilov, MD, Judith Trotman, FRACP, Kerry Taylor, Michael Weichenthal, MD, Jan Walewski, MD, David C. Fisher, MD PhD, Marise McNeeley, Alejandro A. Gru, MD, Yinghui Wang, MS, Maria Corinna Palanca-Wessels, MD PhD, Julie Lisano, Martha Li, Hui-Min Lin, PhD, Meredith Little, MPH, William L. Trepicchio, PhD, Reinhard Dummer, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1646.
https://doi.org/10.1182/blood-2018-99-112847
Published: 2018